Phase 2
N=124
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Metabolic Dysfunction-Associated Steatotic Liver Disease · Non-alcoholic Fatty Liver Disease · Nonalcoholic Fatty Liver Disease · Liver Disease
Bottom Line
View on ClinicalTrials.gov: NCT06482112 ↗Enrolled (actual)
124
Serious AEs
7.3%
Results posted
Jun 2026
Primary outcome: Primary: Mean Relative Reduction From Baseline in Liver Fat Content at Week 28 — 67.8; 54.4; 42.1 Percent Reduction
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Efinopegdutide (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Jun 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Relative Reduction From Baseline in Liver Fat Content at Week 28 |
67.8; 54.4; 42.1 | — |
| PRIMARY Percentage of Participants Who Experienced an Adverse Event (AE) |
83.3; 82.1; 85.7 | — |
| PRIMARY Percentage of Participants Who Discontinued Study Intervention Due to an AE |
7.1; 5.1; 9.5 | — |
| SECONDARY Mean Percent Change From Baseline in Body Weight at Week 28 |
-7.5; -3.9; -4.1 | — |
Summary
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
Eligibility Criteria
Inclusion Criteria
The main inclusion criteria include but are not limited to the following:
- Has body mass index (BMI) ≥25 kg/m^2 (≥23 kg/m^2 for Asian participants) AND has stable weight, defined as ≤5% gain or loss of body weight for at least 3 months before screening
- Has no history of type 2 diabetes mellitus (T2DM) OR has a history of T2DM with a glycated hemoglobin (A1C) ≤9% AND the T2DM is controlled by diet or stable doses of oral antihyperglycemic agents (AHAs)
Exclusion Criteria
The main exclusion criteria include but are not limited to the following
- Has a history or evidence of chronic liver disease other than Metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic dysfunction-associated steatohepatitis (MASH)
- Has evidence of decompensated liver disease including, but not limited to ascites, esophageal or gastric variceal bleeding, hepatocellular carcinoma, hepatic encephalopathy, splenomegaly, or spontaneous bacterial peritonitis
- Has a history of pancreatitis
- Has a history of type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy.
- Has symptomatic hyperglycemia
- Has a history of a bariatric surgical procedure ≤5 years before Screening or a known clinically significant gastric emptying abnormality
- Has a history of obesity with a known secondary cause
- Has significant systemic or major illnesses, including recent (≤6 months before Screening) onset of events of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack
- Is unable to have Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) due to: Claustrophobia to a degree that prevents tolerance of an MRI-PDFF scanning procedure. Note: Sedation is permitted, at the discretion of the investigator; Metallic implants that prevent MRI-PDFF examination; Exceeds the body habitus and/or weight limitations for the MRI scanner
Data sourced from ClinicalTrials.gov (NCT06482112). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.